Cochlear Implant Bilateral denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for cochlear implant bilateral are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Issues a "Not FDA-Approved" Denial for Bilateral Cochlear Implants

This denial is most commonly issued in error or based on an outdated policy interpretation. FDA-cleared cochlear implant systems are approved for use; however, a plan's coverage policy may include language restricting coverage to uses explicitly listed in the original FDA clearance or approval order. When a patient's clinical profile, age range, or hearing loss pattern falls at the edge of a device's labeled indications, a plan may erroneously apply a "not FDA-approved" standard. Bilateral use may also trigger this denial if the plan's policy was drafted when bilateral implantation was less common and has not been updated.

## Why This Denial Is Appealable

FDA clearance and approval status for cochlear implant systems is a matter of public record — the FDA's device database (510(k) and PMA records) is searchable. If the device is cleared or approved for the patient's indication, the denial is factually incorrect and must be overturned. If the plan's policy language is out of step with current FDA status, that is a plan policy issue that can be challenged through the appeals process and, if necessary, external review.

## Your Federal Appeal Rights

• Internal appeal: Respond with official FDA clearance or approval documentation for the specific device and indication. Cite the FDA's device database record by accession number if possible.
• External review (ACA §2719): A denial based on a factual error about FDA status is precisely the type of determination that benefits from independent medical review by a reviewer not employed by BCBS.
• State insurance department complaint: If BCBS upholds a denial that contradicts FDA clearance documentation, filing a complaint with your state insurance commissioner is appropriate. The commissioner can compel the plan to correct factually inaccurate policy language.
• ERISA §503: For employer plans, you are entitled to all clinical and policy criteria used to reach the denial, including any policy provisions that define "FDA-approved."
• Timeline: Internal appeal: typically 180 days from denial notice. External review: typically four months from final internal denial.

## Documentation to Gather

• FDA device clearance / approval records: Print or download the official FDA 510(k) summary or PMA approval letter for the cochlear implant system being requested. This is the most important document for this denial type.
• Device labeling (IFU): The Instructions for Use or FDA-approved labeling document defining the indications for use. Confirm that your patient's clinical profile falls within those indications.
• Prescriber letter: A letter from the implanting surgeon citing the specific FDA-approved indication that applies to this patient, and confirming the requested device and implantation approach fall within it.
• Audiological evaluation: Documentation of the hearing profile in both ears, mapped to the device's labeled indications.

## Criteria-Mapping Structure

Build a direct comparison between the BCBS policy language on FDA approval and the actual FDA record:

| BCBS Policy Requirement | FDA Record Evidence | |---|---| | [Quote the exact policy language defining "FDA-approved" or "FDA-indicated"] | [Cite the specific FDA database record, approval date, and indication language] |

If BCBS's policy definition is narrower than the FDA's own approval language, highlight that discrepancy explicitly in your appeal letter.